Shares of Cancer Genetics Inc. (NASDAQ:CGIX) traded up 3.5% on Wednesday . The stock traded as high as $2.39 and last traded at $2.38, with a volume of 88,739 shares changing hands. The stock had previously closed at $2.30.

Separately, Zacks Investment Research cut Cancer Genetics from a “buy” rating to a “hold” rating in a report on Monday, May 16th.

The firm’s 50-day moving average price is $2.12 and its 200 day moving average price is $2.31. The stock’s market cap is $37.56 million.

Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The firm had revenue of $7 million for the quarter, compared to analysts’ expectations of $6.50 million. During the same quarter last year, the company posted ($0.51) EPS. The firm’s revenue was up 67.3% compared to the same quarter last year. Equities analysts anticipate that Cancer Genetics Inc. will post ($1.19) earnings per share for the current year.

In other news, Director John Pappajohn acquired 147,500 shares of Cancer Genetics stock in a transaction that occurred on Monday, August 15th. The stock was bought at an average price of $2.16 per share, for a total transaction of $318,600.00. Following the completion of the transaction, the director now owns 2,162,387 shares in the company, valued at $4,670,755.92. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.